Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Posters

Search Title by author or title

Posterior lenticonus in congenital cataract surgical treatment

Poster Details

First Author: N.Pashinova RUSSIA

Co Author(s):    K. Pershin   A. Tsygankov   A. Cherkashina              

Abstract Details

Purpose:

Analysis of surgical treatment of children with posterior lenticonus (PL) and congenital cataract (CC).

Setting:

Eximer Eye Center, Moscow, Russian Federation

Methods:

In the period from 2003 to 2015 we examined and operated 107 children (154 eyes) with CC. 8 children (9 eyes) with PL were selected. The average age of the patients was 8.9 �Â�± 3.4 years (1-15). Preoperative UCVA was 0.11 �Â�± 0.1 (0.01-0.3), BCVA 0.15 �Â�± 0.13 (0.01-0.4). Lensectomy was performed under general anesthesia with the microsurgical systems Millenium, Stellaris (Bausch and Lomb, USA) and Infinity (Alcon, USA) using small incisions technology (1.8 mm and 2.2 mm). In all cases the different IOL models (Alcon, USA) were implanted, in four cases - toric IOL.

Results:

In all cases we performed 'dry' aspiration of the lens. Features of posterior capsulorhexis included the use of two viscoelastics: Provisc�Â�® over IOL and Healon5 �Â�© under the IOL as a 'layer cake'. Thereafter, posterior capsulorhexis and vitrectomy were done. Lens is implanted in the capsular bag (haptics), edges of the hole optics were placed behind capsulorhexis hole. BCVA increased from 0.15 to 0.72, astigmatism reduced from 2.3�Â�±0.9 to 1.6�Â�±0.65 D (total astigmatism in the whole group), in a subgroup with toric IOL from 1.81�Â�±0,46D to 0,56�Â�±0,56D in the follow-up of more than 36 months.

Conclusions:

Lensectomy with IOL implantation in posterior lenticonus and congenital cataract is an effective method of treatment. Such features of the surgical technique as 'dry' aspiration of the lens mass, posterior capsulorhexis, anterior vitrectomy and optic capture might achieve high and stable functional results.

Financial Disclosure:

NONE

Back to Poster listing